Bharat Parenterals Subsidiary Innoxel Commences Commercial Supply to the US Market
Bharat Parenterals Ltd · Press Release · 21 Oct 2026, 6:59 pm
Bharat Parenterals Subsidiary Innoxel Commences Commercial Supply to the US Market Bharat Parenterals’ 55.9% subsidiary, Innoxel Lifesciences, commenced commercial supply to the US with its first CMO product launched on 20th Oct'26. Manufactured at its Vadodara facility—holding US FDA EIR (Jul'25) and EU-GMP certification (Mar'26)—this marks the first of two planned FY27 CMO launches. Commercial supply introduces recurring revenue alongside licensing income, which drove all ₹72.4 crore of FY26 revenue (₹17.1 crore upfront, ₹55.3 crore milestone-linked). Innoxel signed 23 deals in FY26 (48 total since inception) and actively partners with 19 entities across the US, EU, and India.
Original exchange filing (PDF)
More announcements from Bharat Parenterals Ltd
- Intimation for receipt of Establishment Inspection Report from US FDA by Innoxel Lifesciences Pvt Ltd., a subsidiary company of Bharat Parenterals Limited. · 05 Nov 2026
- Transcript of Earnings Conference Call of Q2FY27. · 02 Nov 2026
- Audio Recording of Q2FY27 Earnings Conference Call. · 30 Oct 2026
- Investor Presentation for the Quarter and Half Year ended on September 30, 2026. · 29 Oct 2026
- Un-Audited Standalone and Consolidated Financial Results For the Quarter and Half Year Ended On September 30, 2026. · 29 Oct 2026
- Outcome of the Meeting of the Board of Director of Bharat Parenterals Limited held on October 29, 2026 · 29 Oct 2026
- Approval of Preferential Issue by Shareholders of the Company through EGM Held on October 23, 2026. · 25 Oct 2026
- Revised Voting Result · 25 Oct 2026
